The artificial intelligence drug developer has closed a $225m round led by SoftBank Vision Fund 2, which has offered a further $300m in funding.

Koch Disruptive Technologies returned to reinvest in the endpoint cybersecurity software provider, helping boost its overall funding to more than $152m.

Alphabet early-stage investment unit GV has added two biotechnology professionals, Dan Lynch and Mojca Skoberne, to its team.

Allied Minds portfolio company OcuTerra Therapeutics has secured $14.6m in funding.

Renal care provider InterWell Health and skincare product manufacturer Make Essence both raised approximately $46m while Salesforce-backed JazzHR agreed a merger.

Q&A with Gregory Aaron Hoffman, DuPont Electronics & Imaging Ventures

Yale’s immunological and inflammatory disease therapy developer has filed for an offering with an $86.3m placeholder target.

Harvard's T-cell cancer therapy developer has filed to list on the Nasdaq Global Market.

Exor, Coinbase Ventures and DRW Venture Capital have all invested in Crusoe Energy Systems, which owns a network of flared gas-powered data centres.

The Alphabet, Astellas, Novartis and WuXi AppTec-backed T-cell cancer therapy developer has filed to list on the Nasdaq Global Market.